Frankincense Against Knee Osteoarthritis



An enriched extract of the frankincense herb may reduce the symptoms of osteoarthritis. Such were the suggested findings of a study recently reported at Arthritis Research & Therapy.

The authors of the said study have reported that patients who took the enriched herb experienced reduction in pain and increase in mobility in as little as seven days.

The herb was enriched with 30 percent AKBA (3-O-acetyl-11-keto-beta-boswellic acid), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. This enzyme transforms essential fatty acids into leukotrienes, which use signals to regulate the body’s response to inflammation.

AKBA is believed to be the most active ingredient of the B. serrata herb.

“AKBA has anti-inflammatory properties, and we have shown that B. serrata enriched with AKBA can be an effective treatment for osteoarthritis of the knee,” said study leader Siba Raychaudhuri, a faculty member of the University of California, Davis.

“The high incidence of adverse effects associated with currently available medications has created great interest in the search for an effective and safe alternative treatment,” Raychaudhuri said.

Frankincense is something we knew that is used in incense and in perfumes. From wikipedia:

Frankincense is tapped from the very scraggly but hardy Boswellia tree through slashing the bark and allowing the exuded resins to bleed out and harden. These hardened resins are called tears. There are numerous species and varieties of frankincense trees, each producing a slightly different type of resin. Differences in soil and climate create even more diversity in the resin, even within the same species.

In the abovementioned study, the frankincense specie used is Boswellia serrata enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) — a product called 5-Loxin®.

5-Loxin(R) is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-Loxin(R) in the treatment of osteoarthritis (OA) of the knee.

5-Loxin(R) reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin(R) may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.

5-Loxin® is a new, patent-pending joint health ingredient from P.L. Thomas.

Story sources: FOX News, Arthritis Research & Therapy abstract

5-LOXIN is a new, patent-pending joint health ingredient that is steeped in the historic roots of boswellia serrata extracts. The boswellia plant has been used for thousands of years in traditional Ayurvedic medicine in India, and recent studies have shown its benefits in promoting joint comfort, knee mobility and walking distance.

The application of modern science by the researchers at the renowned Laila Impex Research Center in India has resulted in the identification of the most powerful boswellia compound, acetyl-11-keto-beta boswellic acid, or AKBA.

I’m guessing it won’t take too long before this product makes it to the market for public consumption. Soon enough this will be the new osteoarthritis anti-inflammatory/pain drug, don’t you think?

Story sources: FOX News and Arthritis Research & Therapy abstract

Related Posts with Thumbnails
Print Friendly

Comments

  1. This seems to be a boon for people suffering from OA and problems with side effects of existing therapies like cox inhibitors. When can I buy this product? Please make this available quickly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
Roche RA Drug Actemra Wins Support of US FDA Panel

Roche is happy to announce that its rheumatoid arthritis drug Actemra (tocilizumab) has won the recommending approval of the US...

Close